NN9541 / Novo Nordisk - LARVOL DELTA

A Research Study of the New Medicine NNC0519-0130 in Male Chinese Participants Living With Excess Body Weight (clinicaltrials.gov) - P1 | N=20 | Not yet recruiting | Sponsor: Novo Nordisk A/S

New P1 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Research Study to Compare How Much of the Medicine NNC0519-0130 is in the Blood of People With Overweight or Obesity Who Receive 2 Preparations of the Medicine (clinicaltrials.gov) - P1 | N=46 | Completed | Sponsor: Novo Nordisk A/S | Recruiting ➔ Completed

Trial completion • Genetic Disorders • Obesity

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight (clinicaltrials.gov) - P2 | N=355 | Completed | Sponsor: Novo Nordisk A/S | Active, not recruiting ➔ Completed

Trial completion • Genetic Disorders • Obesity

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight (clinicaltrials.gov) - P2 | N=355 | Active, not recruiting | Sponsor: Novo Nordisk A/S | Trial primary completion date: Nov 2024 ➔ Apr 2025

Trial primary completion date • Genetic Disorders • Obesity

A Research Study Looking Into Blood Levels of the Medicine NNC0519-0130 in the Body in Participants With Normal or Reduced Kidney Function (clinicaltrials.gov) - P1 | N=36 | Completed | Sponsor: Novo Nordisk A/S | Trial completion date: Apr 2025 ➔ Nov 2024 | Trial primary completion date: Apr 2025 ➔ Nov 2024 | Active, not recruiting ➔ Completed

Trial completion • Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After Menopause (clinicaltrials.gov) - P1 | N=37 | Active, not recruiting | Sponsor: Novo Nordisk A/S | Trial completion date: Jun 2025 ➔ Oct 2025 | Trial primary completion date: Feb 2025 ➔ Sep 2025

Trial completion date • Trial primary completion date • Diabetes • Long-acting Reversible Contraceptives • Metabolic Disorders • Type 2 Diabetes Mellitus

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease (clinicaltrials.gov) - P2 | N=465 | Recruiting | Sponsor: Novo Nordisk A/S | Trial primary completion date: Aug 2025 ➔ Sep 2026

Trial primary completion date • Chronic Kidney Disease • Diabetes • Genetic Disorders • Metabolic Disorders • Nephrology • Obesity • Renal Disease • Type 2 Diabetes Mellitus

A Research Study Looking Into Blood Levels of the Medicine NNC0519-0130 in the Body in Participants With Normal or Reduced Kidney Function (clinicaltrials.gov) - P1 | N=36 | Active, not recruiting | Sponsor: Novo Nordisk A/S | Recruiting ➔ Active, not recruiting

Enrollment closed • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Research Study of How Safe a New Medicine Called NNC0519 0130 is and to Test Its Effect in People Living With Excess Body Weight With or Without Type 2 Diabetes (clinicaltrials.gov) - P1 | N=64 | Active, not recruiting | Sponsor: Novo Nordisk A/S | Recruiting ➔ Active, not recruiting

Enrollment closed • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease (clinicaltrials.gov) - P2 | N=465 | Recruiting | Sponsor: Novo Nordisk A/S | Not yet recruiting ➔ Recruiting

Enrollment open • Chronic Kidney Disease • Diabetes • Genetic Disorders • Metabolic Disorders • Nephrology • Obesity • Renal Disease • Type 2 Diabetes Mellitus

A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After Menopause (clinicaltrials.gov) - P1 | N=37 | Active, not recruiting | Sponsor: Novo Nordisk A/S | Recruiting ➔ Active, not recruiting

Enrollment closed • Long-acting Reversible Contraceptives

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes (clinicaltrials.gov) - P2 | N=288 | Recruiting | Sponsor: Novo Nordisk A/S | Trial primary completion date: Nov 2024 ➔ Sep 2025

Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease (clinicaltrials.gov) - P2 | N=465 | Not yet recruiting | Sponsor: Novo Nordisk A/S

New P2 trial • Chronic Kidney Disease • Diabetes • Genetic Disorders • Metabolic Disorders • Nephrology • Obesity • Renal Disease • Type 2 Diabetes Mellitus

A Research Study Comparing Different Ways of Increasing the Dose of NNC0519-0130 in Participants With Overweight or Obesity (clinicaltrials.gov) - P1 | N=114 | Recruiting | Sponsor: Novo Nordisk A/S

New P1 trial • Genetic Disorders • Obesity

A Research Study to Compare How Much of the Medicine NNC0519-0130 is in the Blood of People With Overweight or Obesity Who Receive 2 Preparations of the Medicine (clinicaltrials.gov) - P1 | N=46 | Recruiting | Sponsor: Novo Nordisk A/S | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity

A Research Study to Compare How Much of the Medicine NNC0519-0130 is in the Blood of People With Overweight or Obesity Who Receive 2 Preparations of the Medicine (clinicaltrials.gov) - P1 | N=46 | Not yet recruiting | Sponsor: Novo Nordisk A/S

New P1 trial • Genetic Disorders • Obesity

A Research Study of How Safe a New Medicine Called NNC0519 0130 is and to Test Its Effect in People Living With Excess Body Weight With or Without Type 2 Diabetes (clinicaltrials.gov) - P1 | N=64 | Recruiting | Sponsor: Novo Nordisk A/S

New P1 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight (clinicaltrials.gov) - P2 | N=355 | Active, not recruiting | Sponsor: Novo Nordisk A/S | Recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Obesity

A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After Menopause (clinicaltrials.gov) - P1 | N=37 | Recruiting | Sponsor: Novo Nordisk A/S | Not yet recruiting ➔ Recruiting

Enrollment open • Long-acting Reversible Contraceptives

A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After Menopause (clinicaltrials.gov) - P1 | N=37 | Not yet recruiting | Sponsor: Novo Nordisk A/S

New P1 trial • Long-acting Reversible Contraceptives

A Research Study Looking Into Blood Levels of the Medicine NNC0519-0130 in the Body in Participants With Normal or Reduced Kidney Function (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Novo Nordisk A/S | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

NN9541-4842: A Research Study of a New Medicine NNC0519-0130 in Healthy People, People With High Body Weight and People With Type 2 Diabetes. (clinicaltrials.gov) - P1 | N=162 | Completed | Sponsor: Novo Nordisk A/S | Recruiting ➔ Completed | N=114 ➔ 162

Enrollment change • Trial completion • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Novo Nordisk Gets CDSCO Panel Nod To Study New Medicine NNC0519-0130 (Medical Dialogues) - "The drug major Novo Nordisk has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the Phase 2 clinical trial for the new antidiabetic drug NNC0519-0130.This came after Novo Nordisk presented Phase 2 clinical study protocol No.: NN9541-4945 version 2.0 dated 08 January 2024."

New P2 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes (clinicaltrials.gov) - P2 | N=288 | Recruiting | Sponsor: Novo Nordisk A/S | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight (clinicaltrials.gov) - P2 | N=343 | Recruiting | Sponsor: Novo Nordisk A/S | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity